Company Profile

Stronger Sell Today AIMT ranks #5061 as SELL CANDIDATE #5061 Weaker Sell

Aimmune Therapeutics stock forecast

AIMT stock forecast

Aimmune Therapeutics

8000 Marina Boulevard

Brisbane, CA 94005


Industry: Biotechnology

Sector: Healthcare


Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank